TP53 and neoplasm: In contrary, the METTL5 rs3769768 enhanced the risk of EOC in patients with metastasis (adjusted OR=4.965, 95% CI=1.598-15.421, P=0.0056), clinical stage 2 (adjusted OR=5.725, 95% CI=1.508-24.731, P=0.0103), low pathological grade(adjusted OR=5.803, 95%CI=1.779-18.923, P=0.0036), tumor size > 3 cm (adjusted OR=4.453, 95%CI=1.298-15.271, P=0.0175), post-menopause (adjusted OR=4.296, 95% CI=1.464-12.608, P=0.008), high wild p53 expression (adjusted OR=3.177, 95% CI=1.122-8.997, P=0.0296), no mutant p53 expression (adjusted OR=3.699, 95% CI=1.243-11.007, P=0.0187).